AI funding concentration and notable biotech and robotics financing in H1 2026
The first half of 2026 saw $407 bn poured into AI, a $100 m Series B for AI‑driven drug design, OpenAI’s $7 bn employee buy‑back, a robotics acquisition, a Unitree IPO, and a $14.7 m seed round for ocular gene therapy.
Compiled automatically from the sources listed below and checked against Hyperuranios' own capital and research data. Every figure here traces to a linked source. Factual errors reported to the contact address are corrected in the article and noted here.
Artificial Intelligence
According to PitchBook’s H1 2026 AI Report, AI‑focused startups attracted $407 billion in venture capital, more than the total $264 billion invested in the sector during all of 2025. Over half of that amount – roughly $217 billion – went to just two frontier‑model labs, OpenAI and Anthropic, which raised $122 billion in March, $65 billion in a May Series H, and $30 billion in a February Series G round. The remaining capital was spread across 3,500 deals, with vertical‑application firms accounting for 62.9 % of deal count but only 12.9 % of value. The report attributes the concentration to investor confidence in the scaling potential of the leading models [1].
Robotics
Robotic Automation™ announced that it has been acquired by Varley Group, one of Australia’s oldest engineering and manufacturing conglomerates founded in 1886. The deal provides Robotic Automation with the financial backing of a large, Australian‑owned entity and expands its access to engineering resources, project delivery capacity and national service coverage. The acquisition is positioned as a means to strengthen growth, innovation and long‑term customer support while preserving the company’s focus on high‑quality automation solutions for Australian industry. The announcement emphasises continued local employment and the combination of nearly four decades of automation expertise with Varley’s historic manufacturing heritage [3].
A Frontiers in Robotics and AI article on robot dexterity outlines the technical challenges of achieving human‑like manipulation, noting that dexterous tasks require coordinated perception, contact, force, motion and rapid recovery in uncertain environments. The piece argues that tactile sensing, compliant hardware and fast control loops are as critical as artificial intelligence, and that progress should be measured by reliable deployment across varied tasks rather than isolated laboratory successes. It highlights the difficulty of handling deformable, fragile or articulated objects, managing many degrees of freedom, and recovering from slips or collisions, underscoring the gap between locomotion and manipulation in current robotic research [4]. [5]
Unitree, a Hangzhou‑based robot manufacturer, listed on Shanghai’s Star Market in August 2026, raising approximately US$900 million. The IPO attracted 9.8 million online applications for 9.7 million retail shares, resulting in an allocation rate of just 0.018 percent – roughly one winning lot for every 5,500 applicants. The final subscription volume reached 53.64 billion shares, 8,288.82 times the 6.47 million shares initially reserved for retail investors, triggering a clawback mechanism that increased the retail tranche. The offering illustrates the intense demand for Chinese robotics equities and the competitive nature of the Star Market allocation process [6].
Genetic Engineering
Cirrus Therapeutics, a Cambridge‑based ocular‑immunology biotech, expanded its seed financing to $14.7 million after adding the Intellectual Property Company of Cedars‑Sinai to an existing syndicate that includes ClavystBio, Polaris Partners and SEEDS of SG Growth Capital. The round follows an earlier $11 million seed round led by ClavystBio with participation from Polaris Partners and SEEDS. Cirrus is developing a preclinical adeno‑associated virus gene therapy aimed at restoring IRAK‑M in retinal cells to reverse dry age‑related macular degeneration, targeting the underlying cause rather than merely slowing disease progression. The expanded investor base signals confidence in the company’s ambitious therapeutic approach [2].